References
- Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:https://doi.org/10.1056/NEJMoa1509852.
- Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:https://doi.org/10.1016/S0140-6736(16)31339-3.
- Wolf D, D’Haens G, Sandborn WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40(5):486–497. doi:https://doi.org/10.1111/apt.12863.
- Sandborn WJ, Colombel J-F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17(1):141–151. doi:https://doi.org/10.1002/ibd.21328.
- Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167(3):658–667. doi:https://doi.org/10.1111/j.1365-2133.2012.11041.x.
- Putte LBA, van de Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516. doi:https://doi.org/10.1136/ard.2003.013052.
- Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–575. doi:https://doi.org/10.1016/j.jpeds.2006.04.058.
- Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429. doi:https://doi.org/10.2147/OPTH.S23646.
- Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24(3):351–361. doi:https://doi.org/10.1089/jop.2007.0104.
- Durrani K, Kempen JH, Ying G-S, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405–412. doi:https://doi.org/10.3109/09273948.2015.1134581.
- Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gómez J, Merino R. Adalimumab therapy for refractory childhood uveitis. J Aapos. 2013;17(5):456–459. doi:https://doi.org/10.1016/j.jaapos.2013.06.009.
- Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines Committee. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory Bowel disease. Gastroenterology. 2017;153(3):827–834. doi:https://doi.org/10.1053/j.gastro.2017.07.032.
- Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966;76(5):646–661. doi:https://doi.org/10.1001/archopht.1966.03850010648005.
- Abbott Laboratories. 2003. HUMIRA (adalimumab) package insert. https://www.rxabbvie.com/pdf/humira.pdf. Accessed December 24, 2019
- Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286–297. doi:https://doi.org/10.1111/bcp.12509.
- Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143(2):365–374.e2. doi:https://doi.org/10.1053/j.gastro.2012.04.046.
- Leinonen ST, Aalto K, Kotaniemi KM, Kivelä TT. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043–1046.
- Marino A, Real-Fernández F, Rovero P, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. J Clin Rheumatol. 2018;37(5):1407–1411. doi:https://doi.org/10.1007/s10067-018-4057-7.
- Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016;123(12):2618–2625. doi:https://doi.org/10.1016/j.ophtha.2016.08.025.
- Ryan C, Sobell JM, Leonardi CL, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19(3):437–447. doi:https://doi.org/10.1007/s40257-017-0341-6.
- Dubinsky MC, Rosh J, Faubion WA, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2016;22(4):886–893. doi:https://doi.org/10.1097/MIB.0000000000000715.